All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

December 9th 2024

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma

December 9th 2024

Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

December 9th 2024

Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

December 9th 2024

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

December 9th 2024

The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.

Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor–Naive Myelofibrosis

December 9th 2024

Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.

Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma

December 9th 2024

Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia

December 9th 2024

Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

December 9th 2024

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC

December 9th 2024

The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.

Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma

December 9th 2024

Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL

December 9th 2024

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis

December 9th 2024

Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL

December 8th 2024

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL

December 8th 2024

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma

December 8th 2024

Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.

Social Determinants of Health Correlate With Receipt of Allo-HSCT in AML

December 8th 2024

Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL

December 8th 2024

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia